Patents Assigned to Bayer Consumer Care AG
-
Patent number: 11793761Abstract: The disclosure relates to a pharmaceutical or dietary composition in the form of a soft gel capsule comprising a liquid or semisolid fill and a shell, the fill comprising at least one active ingredient or dietary supplement, dissolved, suspended or solubilized in a solution comprising water and alcohol, and a solubilizer and thickening agent. The disclosure furthermore relates to methods of reducing brittleness and fragility of such soft gel capsules.Type: GrantFiled: March 17, 2023Date of Patent: October 24, 2023Assignee: BAYER CONSUMER CARE AGInventors: Aude Barroso, Maria Elena Iglesias, Maria Del Pilar Sanz Saiz, Blanca Alvarez Maluenda, Alberto Prior, Javier Zumeta
-
Publication number: 20220223261Abstract: The present invention relates to the identification of one or more candidate signs indicative of an NTRK oncogenic fusion within patient data. Subject matter of the present invention are a computer-implemented method, a system, and a non-transitory computer-readable storage medium for determining a probability value from patient data associated with a subject patient, the probability value indicating the probability of the subject patient suffering from cancer caused by a mutation of a neurotrophic receptor tyrosine kinase (NTRK) gene.Type: ApplicationFiled: April 28, 2020Publication date: July 14, 2022Applicant: Bayer Consumer Care AGInventors: Arndt SCHMITZ, Eren Metin ELCI, Faidra STAVROPOULOU, Mikhail KACHALA, Antti KARLSSON, Mikko TUKIAINEN
-
Patent number: 11185549Abstract: The present invention relates to: • combinations of: * a component A: which is a PI3K kinase inhibitor, such as copanlisib, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same, for example; * a component B: which is an androgen receptor antagonist, such as darolutamide or enzalutamide for example; and, optionally, * one or more pharmaceutical agents C; in which optionally either or both of said components A and B are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially; • use of such combinations: * in the treatment or prophylaxis of a cancer, particularly prostate cancer, or * for the preparation of a medicament for the treatment or prophylaxis of a cancer, particularly prostate cancer; • methods of treatment or prophylaxis of a cancer, particularly prostate cancer, in a subject, comprising administering to said subjectType: GrantFiled: June 21, 2018Date of Patent: November 30, 2021Assignees: BAYER CONSUMER CARE AG, BAYER PHARMA AKTIENGESELLSCHAFTInventor: Bernard Haendler
-
Publication number: 20200281932Abstract: The present invention relates to: a method of preparing a stable, copanlisib-containing aqueous bulk solution suitable for lyophilisation and for therapeutic applications; a stable, copanlisib-containing bulk solution, of increased solubility which is directly suitable for lyophilisation; a method of lyophilizing such a copanlisib-containing aqueous bulk solution; a stable, lyophilized, copanlisib-containing solid, in particular powder or cake, particularly containing a therapeutic dose of copanlisib in one or two containers, particularly one sealed container; a method of reconstituting such lyophilisates; and a stable, reconstituted, copanlisib-containing solution of increased solubility, suitable for further dilution and for therapeutic applications.Type: ApplicationFiled: September 6, 2018Publication date: September 10, 2020Applicants: Bayer Pharma Aktiengesellschaft, Bayer Consumer Care AGInventors: Julia FREUNDLIEB, Tia JACOBS
-
Publication number: 20200222414Abstract: The present invention relates to: * combinations of: * a component A: which is a PI3K kinase inhibitor, such as co-panlisib, or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, in particular a physiologically acceptable salt, or a mixture of same, for example; * a component B: which is an androgen receptor antagonist, such as darolutamide or enzalutamide for example; and, optionally, * one or more pharmaceutical agents C; in which optionally either or both of said components A and B are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially; * use of such combinations: * in the treatment or prophylaxis of a cancer, particularly prostate cancer, or * for the preparation of a medicament for the treatment or prophylaxis of a cancer, particularly prostate cancer; * methods of treatment or prophylaxis of a cancer, particularly prostate cancer, in a subject, comprising administering to said subjecType: ApplicationFiled: June 21, 2018Publication date: July 16, 2020Applicants: BAYER CONSUMER CARE AG, BAYER PHARMA AKTIENGESELLSCHAFTInventor: Bernard HAENDLER
-
Patent number: 9867789Abstract: The use of a non-steroidal anti-inflammatory drug for the treatment of nonproductive cough caused by viruses or bacteria and a combination of at least one non-steroidal anti-inflammatory drug with at least one antitussive in a formulation to treat coughs.Type: GrantFiled: June 27, 2012Date of Patent: January 16, 2018Assignee: BAYER CONSUMER CARE AGInventors: Marianne Petersen-Braun, Chirin Yekrangi-Hartmann, Uwe Gessner, Michael Völker
-
Patent number: 9498505Abstract: The present invention deals with an Embelia extract—preferably an extract from Embelia concinna titrated in flavonoids—, its process for preparation and its use in a cosmetical or pharmaceutical composition for the treatment of skin sensitivity, for the treatment of allergic reactions of the skin, for soothing and for the treatment of itching skin and for the regulation of inflammatory drifts in the skin.Type: GrantFiled: April 10, 2013Date of Patent: November 22, 2016Assignee: Bayer Consumer Care AGInventors: Virginie Petit, Eric Theron
-
Patent number: 9339521Abstract: The present invention relates to the use of an extract of a Vernonia plant from Madagascar in cosmetics, pharmaceuticals and food supplements for improving the skin status, more specifically by strengthening the dermal-epidermal junction and/or by activating fibroblasts synthesis of dermis and extracellular matrix compounds.Type: GrantFiled: October 16, 2009Date of Patent: May 17, 2016Assignee: BAYER CONSUMER CARE AGInventors: Caroline Segond, Alain Loiseau, Virginie Petit, Eric Theron
-
Patent number: D750885Type: GrantFiled: February 28, 2013Date of Patent: March 8, 2016Assignee: BAYER CONSUMER CARE AGInventors: Bruno Chazel, Sébastien Lucien Fily
-
Patent number: D964552Type: GrantFiled: April 2, 2021Date of Patent: September 20, 2022Assignee: Bayer Consumer Care AGInventor: Michael Best
-
Patent number: D964562Type: GrantFiled: December 31, 2020Date of Patent: September 20, 2022Assignee: Bayer Consumer Care AGInventors: Bruno Chazel, Kory Nook
-
Patent number: D965146Type: GrantFiled: December 31, 2020Date of Patent: September 27, 2022Assignee: Bayer Consumer Care AGInventors: Bruno Chazel, Kory Nook
-
Patent number: D971431Type: GrantFiled: April 2, 2021Date of Patent: November 29, 2022Assignee: Bayer Consumer Care AGInventor: Michael Best
-
Patent number: D971432Type: GrantFiled: April 2, 2021Date of Patent: November 29, 2022Assignee: Bayer Consumer Care AGInventor: Michael Best
-
Patent number: D981001Type: GrantFiled: April 2, 2021Date of Patent: March 14, 2023Assignee: Bayer Consumer Care AGInventor: Michael Best
-
Patent number: D999633Type: GrantFiled: June 5, 2021Date of Patent: September 26, 2023Assignee: Bayer Consumer Care AGInventors: Pil Ho Chung, Mark Prommel
-
Patent number: D999634Type: GrantFiled: June 5, 2021Date of Patent: September 26, 2023Assignee: Bayer Consumer Care AGInventors: Pil Ho Chung, Mark Prommel
-
Patent number: D1004441Type: GrantFiled: June 5, 2021Date of Patent: November 14, 2023Assignee: Bayer Consumer Care AGInventors: Pil Ho Chung, Mark Prommel
-
Patent number: D1011920Type: GrantFiled: June 5, 2021Date of Patent: January 23, 2024Assignee: Bayer Consumer Care AGInventors: Pil Ho Chung, Mark Prommel
-
Patent number: D1011921Type: GrantFiled: June 5, 2021Date of Patent: January 23, 2024Assignee: Bayer Consumer Care AGInventors: Pil Ho Chung, Mark Prommel